Study of Rasburicase Versus Allopurinol in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome
This study has been completed.
Study NCT00230178
Information provided by Sanofi-Aventis
First Received: September 28, 2005
Last Updated: August 27, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
